ALVR Insider Trading

Insider Ownership Percentage: 32.07%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $82,278.96

AlloVir Insider Trading History Chart

This chart shows the insider buying and selling history at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$2.80ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

AlloVir Share Price & Price History

Current Price: $9.71
Price Change: Price Decrease of -0.34 (-3.38%)
As of 02/10/2025 05:00 PM ET

This chart shows the closing price history over time for ALVR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJanFeb$10.05Closing price on 02/09/25:

SEC Filings (Institutional Ownership Changes) for AlloVir (NASDAQ:ALVR)

66.05% of AlloVir stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALVR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$587kbought$4.07MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More on AlloVir

Today's Range

Now: $9.71
Low: $9.61
High: $10.16

50 Day Range

MA: $10.29
Low: $8.77
High: $12.22

52 Week Range

Now: $9.71
Low: $7.96
High: $24.15

Volume

20,504 shs

Average Volume

37,427 shs

Market Capitalization

$48.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Who are the company insiders with the largest holdings of AlloVir?

AlloVir's top insider investors include:
  1. Gilead Sciences, Inc (Major Shareholder)
  2. Vikas Sinha (Insider)
  3. Diana Brainard (CEO)
  4. Edward Miller (General Counsel)
  5. Brett R Hagen (CAO)
Learn More about top insider investors at AlloVir.

Who are the major institutional investors of AlloVir?

AlloVir's top institutional investors include:
  1. BML Capital Management LLC — 3.66%
  2. Raymond James Financial Inc. — 1.20%
Learn More about top institutional investors of AlloVir stock.

Which major investors are selling AlloVir stock?

Within the last quarter, ALVR stock was sold by these institutional investors:
  1. BML Capital Management LLC
During the previous year, company insiders that have sold AlloVir company stock include:
  1. Gilead Sciences, Inc (Major Shareholder)
  2. Vikas Sinha (Insider)
  3. Diana Brainard (CEO)
  4. Edward Miller (General Counsel)
Learn More investors selling AlloVir stock.

Which major investors are buying AlloVir stock?

Within the previous quarter, ALVR stock was bought by institutional investors including:
  1. Raymond James Financial Inc.